| Shriro Holdings Limited (SHM) ORDINARY FULLY PAID |
Consumer Discretionary |
$57 |
Dividend/Distribution - SHM
|
27 Feb 2025 5:01PM |
$0.800 |
$0.800 |
fallen by
0%
|
|
| Shriro Holdings Limited (SHM) ORDINARY FULLY PAID |
Consumer Discretionary |
$57 |
Half Yearly Report and Accounts
|
27 Feb 2025 5:00PM |
$0.800 |
$0.800 |
fallen by
0%
|
|
SHM - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue decreased to $55.9 million, down 12.9% from the previous year.
- EBITDA increased by 3.8% to $10.8 million.
- Operating expenses reduced by 20.2% due to business restructuring.
- Net cash stands at $24.7 million.
- Dividend of 2.0 cents per share declared for the half year.
- Company focused on growth through product development and geographic expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kula Gold Limited (KGD) ORDINARY FULLY PAID |
Materials |
$96 |
Notification regarding unquoted securities - KGD
|
27 Feb 2025 4:58PM |
$0.005 |
$0.080 |
risen by
1,500%
|
|
| Kula Gold Limited (KGD) ORDINARY FULLY PAID |
Materials |
$96 |
Notification regarding unquoted securities - KGD
|
27 Feb 2025 4:57PM |
$0.005 |
$0.080 |
risen by
1,500%
|
|
| Beacon Minerals Limited (BCN) ORDINARY FULLY PAID |
Materials |
$416 |
Appendix 4D and 2024 Half Year Financial Report
|
27 Feb 2025 4:57PM |
$0.025 |
$3.740 |
risen by
14,860%
|
|
BCN - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue for the half-year was $41,048,563.
- The company reported a loss from ordinary activities after tax of $7,280,066.
- Gold sales totaled 10,927 ounces at an average price of $3,914 per ounce.
- Operational highlights include 12,091 ounces of gold produced.
- The Iguana Deposit at Lady Ida has a mineral resource estimate of 609,000 ounces.
- Completed a $10.3 million entitlement issue fully underwritten.
- Exploration activities focused on the Tycho and MacPherson leases.
- Joint venture agreement for Lady Ida Project executed.
- No dividends declared for the period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kula Gold Limited (KGD) ORDINARY FULLY PAID |
Materials |
$96 |
Application for quotation of securities - KGD
|
27 Feb 2025 4:56PM |
$0.005 |
$0.080 |
risen by
1,500%
|
|
| Asara Resources Limited (AS1) ORDINARY FULLY PAID |
Materials |
$192 |
Becoming a substantial holder
|
27 Feb 2025 4:56PM |
$0.034 |
$0.120 |
risen by
252.94%
|
|
| Brainchip Holdings Ltd (BRN) ORDINARY FULLY PAID |
Information Technology |
$338 |
LDA Capital Call Notice
|
27 Feb 2025 4:55PM |
$0.258 |
$0.150 |
fallen by
41.75%
|
|
BRN - Price-sensitive ASX Announcement
Full Release
Key Points
- BrainChip issues Capital Call Notice to LDA Capital to sell up to 40,000,000 shares
- Available funding under the LDA Agreement stands at AUD $74.8M
- Company commences search for a Senior Operations Manager to support its operations
- Company obligated to advance a minimum of 40 million shares to LDA by June 30, 2025
- Issue price of shares will be 91.5% of the higher daily volume weighted average price
- Company intends to use capital to execute on product roadmap and development initiatives
- Significant expansion of the Company’s portfolio of proprietary TENNs based models underway
- Enhancements to the Akida 2.0 platform aimed at a release in the second half of 2025
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cleo Diagnostics Ltd (COV) ORDINARY FULLY PAID |
Health Care |
$85 |
Appendix 4D and Half Yearly Accounts
|
27 Feb 2025 4:53PM |
$0.505 |
$0.620 |
risen by
22.77%
|
|
COV - Price-sensitive ASX Announcement
Full Release
Key Points
- Cleo Diagnostics is developing a blood test for early ovarian cancer diagnosis.
- The test utilizes a patented CXCL10 biomarker.
- Clinical trials have commenced in the U.S. and Australia.
- FDA-enabling trials involve patient recruitment of at least 500 individuals.
- The company plans to submit its application to the FDA by the end of 2025.
- Cleo's financial loss decreased to $1,950,364 for the half-year ended December 2024.
- Cash reserves at the end of the reporting period amounted to $7.311M.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cadence Opportunities Fund Limited (CDO) ORDINARY FULLY PAID |
Financials |
$34 |
Media Release - Half Year Results
|
27 Feb 2025 4:50PM |
$1.700 |
$2.150 |
risen by
26.47%
|
|
CDO - Price-sensitive ASX Announcement
Full Release
Key Points
- Half-year loss after tax of $0.3 million.
- Portfolio down 1.1% over six months.
- Top performance contributors included Echo IQ, Netflix, and Iperionx.
- Major detractors included Whitehaven Coal and BHP.
- Downturn in commodity prices adversely affected investment performance.
- Positive returns from Netflix and Meta Platforms due to turnaround strategies.
- Participation in Echo IQ equity raise provided excellent returns.
- 6.5 cent fully franked interim dividend declared.
- Annualised yield of 7.6% fully franked.
- CDO trading at a 12% discount to NTA.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brainchip Holdings Ltd (BRN) ORDINARY FULLY PAID |
Information Technology |
$338 |
BrainChip Evaluates Redomiciling to US
|
27 Feb 2025 4:50PM |
$0.258 |
$0.150 |
fallen by
41.75%
|
|
BRN - Price-sensitive ASX Announcement
Full Release
Key Points
- BrainChip to investigate redomiciling to the US in 2025
- Decision made after extensive strategic review by the Board
- Aim to list on a US-based securities exchange
- Existing shareholders to hold equivalent US-listed securities
- US market provides a larger and more technologically savvy investor base
- Potential for positive re-evaluation and re-pricing of shares
- SEC rules offer greater protection for sensitive information
- Delisting from ASX to reduce regulatory compliance and costs
- Chairman believes decision is in the best interest of all stakeholders
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cadence Opportunities Fund Limited (CDO) ORDINARY FULLY PAID |
Financials |
$34 |
Dividend/Distribution - CDO
|
27 Feb 2025 4:45PM |
$1.700 |
$2.150 |
risen by
26.47%
|
|
| Sims Limited (SGM) ORDINARY FULLY PAID |
Materials |
$4,081 |
Change in substantial holding
|
27 Feb 2025 4:44PM |
$14.720 |
$21.120 |
risen by
43.48%
|
|
| Asara Resources Limited (AS1) ORDINARY FULLY PAID |
Materials |
$192 |
Change in substantial holding
|
27 Feb 2025 4:42PM |
$0.034 |
$0.120 |
risen by
252.94%
|
|
| Asara Resources Limited (AS1) ORDINARY FULLY PAID |
Materials |
$192 |
Change in substantial holding
|
27 Feb 2025 4:41PM |
$0.034 |
$0.120 |
risen by
252.94%
|
|
| Cadence Opportunities Fund Limited (CDO) ORDINARY FULLY PAID |
Financials |
$34 |
Appendix 4D Half Year Report 31 December 2024
|
27 Feb 2025 4:39PM |
$1.700 |
$2.150 |
risen by
26.47%
|
|
CDO - Price-sensitive ASX Announcement
Full Release
Key Points
- Operating loss before tax of $488,824
- Operating loss after tax of $271,542
- Gross performance of -1.1%
- Net investments valued at $27,630,291
- Net asset value decreased to $31,587,302
- Declared interim dividend of 6.5 cents per share
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tissue Repair Ltd (TRP) ORDINARY FULLY PAID |
Health Care |
$11 |
Appendix 4D and Half Year Report to 31 December 2024
|
27 Feb 2025 4:37PM |
$0.270 |
$0.190 |
fallen by
29.63%
|
|
TRP - Price-sensitive ASX Announcement
Full Release
Key Points
- Tissue Repair is a clinical stage biopharmaceutical company developing advanced wound healing products.
- The Group recorded a loss of $2,560,868 for the six months ending 31 December 2024.
- TR987® for treatment of chronic wounds has entered Phase 3 trials in the US.
- TR Pro+® sales increased by 35% in Q4 2024, with monthly sales peaking at $45k.
- The company is in advanced discussions for distribution partnerships in Australia and New Zealand.
- A total of more than 30 clinical sites have been identified across the US and Australia for TR987® trials.
- The FDA has been approached for a reclassification of TR987® as a biological product.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nagambie Resources Limited (NAG) ORDINARY FULLY PAID |
Materials |
$15 |
Production Target Retraction and Replacement Announcement
|
27 Feb 2025 4:36PM |
$0.017 |
$0.016 |
fallen by
5.88%
|
|
NAG - Price-sensitive ASX Announcement
Full Release
Key Points
- Nagambie Resources Limited is retracting the previously announced production target.
- The production target had not been disclosed in compliance with ASX Listing Rule 5.16.
- The production target was described as conceptual and its feasibility is currently unknown.
- New drilling results indicate high-grade antimony-gold intersections.
- The company reaffirmed that all material assumptions underpinning the current JORC Mineral Resource Estimation (MRE) remain valid.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| St George Mining Limited (SGQ) ORDINARY FULLY PAID |
Materials |
$366 |
Change of Director's Interest Notice x3
|
27 Feb 2025 4:35PM |
$0.021 |
$0.096 |
risen by
357.14%
|
|
| X2M Connect Limited (X2M) ORDINARY FULLY PAID |
Information Technology |
$6 |
FY25 Half Year results
|
27 Feb 2025 4:35PM |
$0.020 |
$0.006 |
fallen by
70%
|
|
| X2M Connect Limited (X2M) ORDINARY FULLY PAID |
Information Technology |
$6 |
Half Yearly Report and Accounts
|
27 Feb 2025 4:35PM |
$0.020 |
$0.006 |
fallen by
70%
|
|
X2M - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenues from ordinary activities were $3.4 million, down 55% on the pcp
- Recurring SaaS and maintenance revenue was $0.8 million, flat on pcp
- Gross margin was 47%, up 10 percentage points on the pcp
- Operating expenditure was $3.2 million, down by 31% on the pcp
- 1H25 cash burn from operating activities was $1.8 million
- South Korea segment continued to be profitable delivering positive EBITDA of $0.1 million
- 7 new enterprise and government customers were acquired bringing the total customer base to 80
- Connected devices were 544,910, up 5% on the pcp
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cadence Capital Limited (CDM) ORDINARY FULLY PAID |
Financials |
$238 |
Media Release - Half Year Results
|
27 Feb 2025 4:33PM |
$0.690 |
$0.800 |
risen by
15.94%
|
|
CDM - Price-sensitive ASX Announcement
Full Release
Key Points
- Half year loss after tax of $7.8 million
- Portfolio down 3.6% over the half year
- Top contributors included Netflix and Meta Platforms
- Major detractors were Whitehaven Coal and BHP
- Interim dividend of 3 cents per share declared
- Annualized yield of 8.7% based on the interim dividend
- Ongoing on-market buy-back of shares issued in DRP
- CDM shares trading at an 11% discount to NTA
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Global X S&P 500 Covered Call ETF (UYLD) |
Financials |
$13 |
Global X Updated Est Distribution Announcement - Feb 2025
|
27 Feb 2025 4:32PM |
$12.120 |
$10.470 |
fallen by
13.61%
|
|
| Global X Australian Bank Credit ETF (BANK) |
Financials |
$175 |
Global X Updated Est Distribution Announcement - Feb 2025
|
27 Feb 2025 4:32PM |
$10.040 |
$10.010 |
fallen by
0.30%
|
|
| Global X Nasdaq 100 Covered Call ETF (QYLD) |
Financials |
$21 |
Global X Updated Est Distribution Announcement - Feb 2025
|
27 Feb 2025 4:32PM |
$12.390 |
$10.790 |
fallen by
12.91%
|
|